PROTECT PHARMACEUTICAL CORP
PROTECT PHARMACEUTICAL CORP (PRTT): 2 pipeline candidates · ~2151 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2150.6 months
D/E -1.13 · 22% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for PROTECT PHARMACEUTICAL CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.3M
Cash
$20K
Quarterly Burn
$28
Runway
2150.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in PROTECT PHARMACEUTICAL CORP's pipeline?
PROTECT PHARMACEUTICAL CORP (PRTT) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROTECT PHARMACEUTICAL CORP's lead drug candidate?
PROTECT PHARMACEUTICAL CORP's most advanced tracked candidate is prtt-200 (Preclinical) for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy.
What is PROTECT PHARMACEUTICAL CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROTECT PHARMACEUTICAL CORP has approximately 2150.6 months of cash runway.
What is PROTECT PHARMACEUTICAL CORP's market capitalization?
PROTECT PHARMACEUTICAL CORP's market capitalization is approximately $6.3M.
Get the full picture on PROTECT PHARMACEUTICAL CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.